The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial aimed to attribute metastatic gastric cancer patients to specific targeted drugs based on eight different biomarker groups identified by NGS (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, and MET overexpression all negative, TSC2 deficient, or RICTOR amplification). The gene discussed is TP53; the disease is gastric cancer.